Skip to main content
. Author manuscript; available in PMC: 2015 Jan 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):57–64. doi: 10.1097/QAI.0b013e3182a99a0d

Table 1.

Characteristics of HAART initiators in the Multicenter AIDS Cohort Study by Calendar Period at HAART Initiation

Participant characteristics at HAART initiation 1996-2001 2002-2005 2006/2009 P value
(n=690) (n=189) (n=130)
Race/Ethnicity <0.001
 Hispanic (%) 6 13 16
 Non-white (%) 12 34 28
Baseline education
 >= College (%)
53 44 37 <0.001
History of IDU(%) 14 14 18 0.591
Chronic HBV (%) 8 8 8 1.0
Chronic HCV (%) 6 9 8 0.321
Age (years): Med
 (IQR)
43
(39-48)
43
(37-49)
47
(39-53)
0.005
Hyperglycemia/DM* (% of prevalence) 8.3 13.2 18.7 <0.001
Hyperlipidemia *(% of prevalence) 58.9 28.1 35.2 <0.001
CD4 count (cells/μl) Nadir:
Med (IQR)
211
(109-321)
278
(154-373)
310
(214-419)
<0.001
CD4 count (cells/μl) Pre-HAART:
Med (IQR)
302
(164-461)
329
(193-432)
380
(237-527)
<0.001
Pre-HAART RNA (log10 cp/mL):
Med (IQR)
4.4 (3.5-4.9) 4.6 (3.9-5.1) 4.5 (4.0-5.0) 0.046

P values were obtained from the Fisher exact test or the Kruskal-Wallis non-parametric test, as appropriate.

Med = median, IQR = interquartile range

*

among pre-HAART HIV-infected person-visits by calendar periods.

Hyperglycemia/diabetes mellitus was defined as FG<110mg/dL or self-report of high blood sugar or on anti-diabetic drug Hyperlipidemia was defined as fasting total cholesterol > 210 mg/dL or self report of high total cholesterol or triglycerides or on lower-lipids medication.